Link to this page
Biological and Environmental Research Ontology
| Preferred Name | Leuprolide Acetate | |
| Synonyms |
|
|
| Definitions |
The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1319 |
|
| Accepted_Therapeutic_Use_For |
Endometriosis; In-vitro fertilization; Precocious puberty; Premenstrual syndrome; Prostate cancer; Uterine fibroid tumors
|
|
| ALT_DEFINITION |
A drug used to treat symptoms of advanced prostate cancer. It is also being studied in the treatment of other conditions and types of cancer. The active ingredient leuprolide blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. Some brands of leuprolide are also used to treat early puberty in children and certain gynecologic conditions. Leuprolide acetate is a type of gonadotropin-releasing hormone analog.
|
|
| CAS_Registry |
74381-53-6
|
|
| CHEBI_ID |
CHEBI:63597
|
|
| Chemical_Formula |
C59H84N16O12.C2H4O2
|
|
| code |
C1319
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.
|
|
| Display_Name |
Leuprolide Acetate
|
|
| FDA_UNII_Code |
37JNS02E7V
|
|
| Has_Free_Acid_Or_Base_Form | ||
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Leuprolide Acetate
|
|
| Legacy Concept Name |
Leuprolide
|
|
| Maps_To |
Leuprolide Acetate
|
|
| NCI_Drug_Dictionary_ID |
40058
|
|
| NSC Number |
377526
|
|
| PDQ_Closed_Trial_Search_ID |
40058
|
|
| PDQ_Open_Trial_Search_ID |
40058
|
|
| Preferred_Name |
Leuprolide Acetate
|
|
| prefixIRI |
NCIT:C1319
|
|
| prefLabel |
Leuprolide Acetate
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance
|
|
| UMLS_CUI |
C0700596
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |